Overview
Othelium Therapeutics is developing first-in-class biologics to restore endothelial function and treat microvascular disease and heart failure.
Othelium Therapeutics
Cambridge, MA
& metabolic, Biologics, Cardiovascular, endocrine, Immunology & inflammation, renal
Leadership
-
Emily Ricq, PhD
CEO
-
Tim Hla, PhD
Investigator, Vascular Biology Program, Boston Children's Hospital; Chair and Professor, Patricia K. Donohoe, Department of Surgery, Harvard Medical School